Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Opioid-Related Disorders 1

Interventions

pembrolizumab 64Carboplatin 63Paclitaxel 54Magnetic Resonance Spectroscopy 45Specimen Handling 43Cisplatin 43Gemcitabine 35Bevacizumab 31Docetaxel 30Doxorubicin 29Leucovorin 28Fluorouracil 27Dexamethasone 27Cyclophosphamide 26Pemetrexed 25Radiation 23Oxaliplatin 23Radiotherapy 22Etoposide 22durvalumab 21Nivolumab 21Letrozole 21Vincristine 20Rituximab 20Irinotecan 20Taxes 19Prednisone 19Capecitabine 19Lenalidomide 18130-nm albumin-bound paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Olanzapine × 30 days × Clear all
NCT06200181 2026-06-01

Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial

M.D. Anderson Cancer Center

Phase 3 Recruiting
87 enrolled

Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡